跳至主要内容
临床试验/NCT00554346
NCT00554346已完成4 期

A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2008年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
64
试验地点
1
主要终点
Pain at rest at different timepoint after surgical procedures

研究概览

简要总结

Post surgical pain associated with ligament reconstruction may persist for few days after the surgical procedure. Arcoxia is a new anti-inflammatory and analgesic drug that alleviate pain through oral administration. This study will test the safety and efficacy of Arcoxia in the management of post-operational pain in patients receive the ligament reconstruction surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
16 Years 至 35 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women age ranged from 16~35 who have anterior cruciate ligament injury and/or associated injuries are scheduled for ACL reconstruction surgery.
  • Patient agrees to participate into this study and is willing to sign the patient informed consent form.

排除标准

  • 未提供

研究组 & 干预措施

1

Active Comparator

Etoricoxib 90mg

干预措施: Arcoxia(etoricoxib 90 mg/tablet) (Drug)

2

Placebo Comparator

placebo

干预措施: Arcoxia(etoricoxib 90 mg/tablet) (Drug)

结局指标

主要结局

Pain at rest at different timepoint after surgical procedures

时间窗: From baseline(preoperation) to 3 days after

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

A Randomized, Double Blind, Placebo-controlled Study... | 临床试验